Rivastigmine is a medication commonly used to treat symptoms of dementia, including Alzheimer’s disease and Parkinson’s disease-related dementia. While it can help improve cognitive function, it also comes with several side effects that users should be aware of.
The most frequent side effects of rivastigmine include nausea, vomiting, and diarrhea. These gastrointestinal issues are common, especially when starting the medication or increasing the dose. Many patients also experience loss of appetite and weight loss. Other digestive problems such as indigestion may occur as well.
Fatigue and weakness are also reported, along with dizziness and headaches. Some people may feel drowsy or have trouble sleeping, experiencing insomnia. Mental effects like confusion, agitation, anxiety, restlessness, and tremors have been noted in some cases.
Because rivastigmine affects the nervous system, it can cause symptoms such as tremors and dizziness, which may increase the risk of falls. Patients are advised to be cautious when driving or operating machinery until they know how the drug affects them.
Skin reactions can occur, especially with the rivastigmine patch form. These include redness, itching, or irritation at the application site. Such reactions are reported in a significant number of users.
More serious side effects, though less common, include seizures or convulsions. If these occur, medical attention should be sought immediately. People with peptic ulcers should be careful, as rivastigmine may worsen stomach pain or cause bleeding.
Overall, many side effects tend to lessen as the body adjusts to the medication. However, if side effects are severe or persistent, consulting a healthcare provider is important to manage symptoms or adjust treatment.
Sources
https://www.1mg.com/drugs/rivamer-1.5-capsule-30987
https://www.droracle.ai/articles/489966/can-a-different-generic-brand-of-rivastigmine-cholinesterase-inhibitor
https://www.goodrx.com/compare/aricept-vs-exelon
https://psychopharmacologyinstitute.com/section/dementia-pharmacotherapy-from-cholinesterase-inhibitors-to-anti-amyloid-therapies/
